MedTrace Logo

A Study to Evaluate the Safety and Effectiveness of FK778 in Liver Transplant Patients

NCT00451932 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 303

Last updated 2008-04-17

No results posted yet for this study

Summary

A proof of concept study to evaluate the safety and effectiveness of FK778 in liver transplant patients.

Conditions

  • Liver Transplantation

Interventions

DRUG

FK778

Sponsors & Collaborators

  • Astellas Pharma Inc

    lead INDUSTRY

Principal Investigators

  • Use Central Contact · Universitätsklinik Charité

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-10-31
Primary Completion
2005-09-30
Completion
2005-09-30

Countries

  • Austria
  • Belgium
  • Canada
  • Czechia
  • France
  • Germany
  • Hungary
  • Italy
  • Netherlands
  • Spain
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00451932 on ClinicalTrials.gov